Personal information

Emails & domains

Verified email addresses

Websites & social links

Linkedin

Keywords

Drug development, Brain Tumor, Hematology, Oncology, Pediatric, Metaanalysis, Clinical Trial, Cell Culture, Blood-Brain Barrier, Chemotherapy, Cellular Therapy, Drug Safety, Real Wolrd Evidence

Countries

United States, Germany, Canada

Activities

Collapse all

Employment (13)

Oncology Consulting Wolff LLC: PUYALLUP, WA, US

2024-01-01 to present | CMO and founder (Consuting)
Employment
Source: Self-asserted source
Johannes Wolff

Nurix (United States): San Francisco, US

2023-05 to 2023-12 | VP (Clinical Development)
Employment
Source: Self-asserted source
Johannes Wolff

SPARX Biopharmacuetical Corp Chicago: Chicago, IL, US

2023-03-01 to 2023-05-01 | CMO (CMO)
Employment
Source: Self-asserted source
Johannes Wolff

Replimune: Waltham, MA, US

2022-03 to 2023-03 | VP (Clinincal Development)
Employment
Source: Self-asserted source
Johannes Wolff

AbbVie Inc: North Chicago, IL, US

2017-03 to 2022-05 | Senor medical Director (Clin dev and Safety )
Employment
Source: Self-asserted source
Johannes Wolff

Novartis Pharmaceuticals Corp: East Hanover, NJ, US

2015-12 to 2017-03 | senior medical director (CDMA)
Employment
Source: Self-asserted source
Johannes Wolff

Cleveland Clinic: Cleveland, OH, US

2013-10 to 2015-12 | Depertmetn chair, professor (Pediatric hematology Oncology and Blood and Marrow Transplantation)
Employment
Source: Self-asserted source
Johannes Wolff

Tufts Medical Center: Boston, MA, US

2010-09 to 2013-09 | Division Chief, Professor (Pediatrics)
Employment
Source: Self-asserted source
Johannes Wolff

The University of Texas MD Anderson Cancer Center Children's Cancer Hospital: Houston, TX, US

2005-03-15 to 2010-08 | Section Head, professor (pediatrics)
Employment
Source: Self-asserted source
Johannes Wolff

Kinderklinik Regensburg: Regensburg, DE

2001-01-01 to 2005-02 | Leitender Arzt (Kinderonkologie)
Employment
Source: Self-asserted source
Johannes Wolff

Alberta Children's Hospital: Calgary, AB, CA

1997-05 to 2001-01 | Attending, Associate Professor (Pediatric Oncology)
Employment
Source: Self-asserted source
Johannes Wolff

Universitatsklinikum Munster: Munster, Nordrhein-Westfalen, DE

1991-09 to 1997-05 | Privat Dozent (Pediatric Hematology oncology)
Employment
Source: Self-asserted source
Johannes Wolff

Kennedy Krieger Institute: Baltimore, Maryland, US

1990-03 to 1991-08 | Fellow (Research - neurovascular biology )
Employment
Source: Self-asserted source
Johannes Wolff

Education and qualifications (5)

Bayerische Arztekammer : Muenchen, Bayern, DE

2004-12 | Paediatrischer Haemato-Onkologe (Medicine )
Education
Source: Self-asserted source
Johannes Wolff

Westfälische Wilhelms-Universität Münster: Munster, Nrdrhein-Westfalen, DE

1994-12 | Dr. med. habil - Privat Dozent (Medicine)
Qualification
Source: Self-asserted source
Johannes Wolff

Ärztekammer Westfalen-Lippe: Munster, Nordrhein-Westfalen, DE

1986 to 1993-05 | Pediatrician / Kinderarzt (Medicine)
Education
Source: Self-asserted source
Johannes Wolff

Ruhr-Universität Bochum: Bochum, Nordrhein-Westfalen, DE

1987-02 | PhD (Dr. med.) (Biomechanics)
Qualification
Source: Self-asserted source
Johannes Wolff

Johannes Gutenberg-Universität Mainz Gutenberg Forschungskolleg: Mainz, Rheinland-Pfalz, DE

1986 | Medical Doctor (Medical school )
Qualification
Source: Self-asserted source
Johannes Wolff

Works (50 of 127)

Items per page:
Page 1 of 3

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics & Systems Pharmacology
2025-03 | Journal article
DOI: 10.1002/psp4.13284
Contributors: Neha Thakre; Corinna Maier; Jiuhong Zha; Benjamin Engelhardt; Johannes E. Wolff; Sven Mensing
Source: check_circle
Crossref

Anemia in Placebo Arms of Cancer Studies.

Anticancer research
2021-09-01 | Journal article
DOI: 10.21873/anticanres.15266
PMID: 34475081
Source: Self-asserted source
Johannes Wolff

Headache Reporting in Oncology Trials Depends on the Demographics of the Study Population.

In vivo (Athens, Greece)
2021-07-01 | Journal article
DOI: 10.21873/invivo.12460
PMID: 34182466
PMC: PMC8286522
Source: Self-asserted source
Johannes Wolff

A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Cancer
2021-05-02 | Journal article
DOI: 10.1002/cncr.33590
PMID: 33934351
PMC: PMC8360206
Source: Self-asserted source
Johannes Wolff

Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)].

Leukemia research
2021-04-23 | Journal article
DOI: 10.1016/j.leukres.2021.106581
PMID: 33896620
Source: Self-asserted source
Johannes Wolff

A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival.

Leukemia research
2021-03-02 | Journal article
DOI: 10.1016/j.leukres.2021.106555
PMID: 33705966
Source: Self-asserted source
Johannes Wolff

Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi).

Case reports in hematology
2020-12-15 | Journal article
DOI: 10.1155/2020/8830123
PMID: 33381331
PMC: PMC7758129
Source: Self-asserted source
Johannes Wolff

Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment.

PloS one
2020-01-23 | Journal article
DOI: 10.1371/journal.pone.0227693
PMID: 31971950
PMC: PMC6977734
Source: Self-asserted source
Johannes Wolff

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research
2019-08-16 | Journal article
DOI: 10.1158/1078-0432.ccr-19-0578
PMID: 31420359
Source: Self-asserted source
Johannes Wolff

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.

Skeletal muscle
2019-05-21 | Journal article
DOI: 10.1186/s13395-019-0198-x
PMID: 31113472
PMC: PMC6528217
Source: Self-asserted source
Johannes Wolff

The HDAC3-SMARCA4-miR-27a axis promotes expression of the <i>PAX3:FOXO1</i> fusion oncogene in rhabdomyosarcoma.

Science signaling
2018-11-20 | Journal article
DOI: 10.1126/scisignal.aau7632
PMID: 30459282
PMC: PMC6432638
Source: Self-asserted source
Johannes Wolff

Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma.

Journal of pediatric hematology/oncology
2017-11-01 | Journal article
DOI: 10.1097/mph.0000000000000965
PMID: 28859040
PMC: PMC5657537
Source: Self-asserted source
Johannes Wolff

Choroid plexus tumors in adult and pediatric populations: the Cleveland Clinic and University Hospitals experience.

Journal of neuro-oncology
2017-03-13 | Journal article
DOI: 10.1007/s11060-017-2384-1
PMID: 28290001
Source: Self-asserted source
Johannes Wolff

Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options.

Oncotarget
2016-07-01 | Journal article
DOI: 10.18632/oncotarget.10089
PMID: 27323832
PMC: PMC5216796
Source: Self-asserted source
Johannes Wolff

Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups.

Neuro-oncology
2016-01-28 | Journal article
DOI: 10.1093/neuonc/nov322
PMID: 26826203
PMC: PMC4864264
Source: Self-asserted source
Johannes Wolff

American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Neuro-oncology
2016-01-01 | Journal article
DOI: 10.1093/neuonc/nov297
PMID: 26705298
PMC: PMC4690545
Source: Self-asserted source
Johannes Wolff

Lumbar spinal atypical teratoid rhabdoid tumor.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2015-07-30 | Journal article
DOI: 10.1016/j.jocn.2015.06.007
PMID: 26234633
Source: Self-asserted source
Johannes Wolff

Pediatric atypical choroid plexus papilloma reconsidered: increased mitotic activity is prognostic only in older children.

Acta neuropathologica
2015-05-03 | Journal article
DOI: 10.1007/s00401-015-1434-z
PMID: 25935663
Source: Self-asserted source
Johannes Wolff
grade
Preferred source (of 2)‎

Radiation therapy for choroid plexus carcinoma patients with Li-Fraumeni syndrome: advantageous or detrimental?

Anticancer research
2015-05-01 | Journal article
PMID: 25964589
Source: Self-asserted source
Johannes Wolff

High-resolution genomic analysis does not qualify atypical plexus papilloma as a separate entity among choroid plexus tumors.

Journal of neuropathology and experimental neurology
2015-02-01 | Journal article
DOI: 10.1097/nen.0000000000000154
PMID: 25575132
Source: Self-asserted source
Johannes Wolff
grade
Preferred source (of 2)‎

Neuropsychological short assessment of disease- and treatment-related intelligence deficits in children with brain tumours.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2015-01-09 | Journal article
DOI: 10.1016/j.ejpn.2014.12.019
PMID: 25617910
Source: Self-asserted source
Johannes Wolff

Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.

Neuro-oncology
2015-01-01 | Journal article
DOI: 10.1093/neuonc/nou327
PMID: 25542864
PMC: PMC4277295
Source: Self-asserted source
Johannes Wolff

A novel trial of topotecan, ifosfamide, and carboplatin (TIC) in children with recurrent solid tumors.

Pediatric blood & cancer
2014-11-08 | Journal article
DOI: 10.1002/pbc.25309
PMID: 25382188
Source: Self-asserted source
Johannes Wolff

Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.

Neuro-oncology
2014-05-20 | Journal article
DOI: 10.1093/neuonc/nou091
PMID: 24847085
PMC: PMC4201068
Source: Self-asserted source
Johannes Wolff

Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis.

Genes, chromosomes & cancer
2014-01-30 | Journal article
DOI: 10.1002/gcc.22148
PMID: 24478045
Source: Self-asserted source
Johannes Wolff

Preliminary experience with diffusion tensor imaging before and after re-irradiation treatments in children with progressive diffuse pontine glioma.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2014-01-07 | Journal article
DOI: 10.1007/s00381-013-2350-y
PMID: 24395582
Source: Self-asserted source
Johannes Wolff

How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity?

Pediatric blood & cancer
2013-09-13 | Journal article
DOI: 10.1002/pbc.24770
PMID: 24038885
Source: Self-asserted source
Johannes Wolff

Etoposide improves survival in high-grade glioma: a meta-analysis.

Anticancer research
2013-08-01 | Journal article
PMID: 23898097
Source: Self-asserted source
Johannes Wolff

Cerebellar location may predict an unfavourable prognosis in paediatric high-grade glioma.

British journal of cancer
2013-07-18 | Journal article
DOI: 10.1038/bjc.2013.404
PMID: 23868007
PMC: PMC3749574
Source: Self-asserted source
Johannes Wolff

Loss of TP53 expression in immortalized choroid plexus epithelial cells results in increased resistance to anticancer agents.

Journal of neuro-oncology
2012-07-05 | Journal article
DOI: 10.1007/s11060-012-0915-3
PMID: 22763759
Source: Self-asserted source
Johannes Wolff

A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and Toxicity.

Journal of statistical planning and inference
2012-04-01 | Journal article
DOI: 10.1016/j.jspi.2011.10.016
PMID: 22228921
PMC: PMC3249838
Source: Self-asserted source
Johannes Wolff

Unusual cases: melanomatosis and nephroblastomatosis treated with hyperthermic intraperitoneal chemotherapy.

Journal of pediatric surgery
2012-04-01 | Journal article
DOI: 10.1016/j.jpedsurg.2011.12.018
PMID: 22498396
Source: Self-asserted source
Johannes Wolff

Salvage craniospinal irradiation with an intensity modulated radiotherapy technique for patients with disseminated neuraxis disease.

Practical radiation oncology
2012-02-16 | Journal article
DOI: 10.1016/j.prro.2012.01.004
PMID: 24674188
Source: Self-asserted source
Johannes Wolff

Palliative reirradiation for progressive diffuse intrinsic pontine glioma.

American journal of clinical oncology
2012-02-01 | Journal article
DOI: 10.1097/coc.0b013e318201a2b7
PMID: 21297433
Source: Self-asserted source
Johannes Wolff

Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown.

Journal of the Royal Statistical Society. Series C, Applied statistics
2012-01-01 | Journal article
DOI: 10.1111/j.1467-9876.2011.01002.x
PMID: 22408277
PMC: PMC3298417
Source: Self-asserted source
Johannes Wolff

Preliminary experience with personalized and targeted therapy for pediatric brain tumors.

Pediatric blood & cancer
2011-12-11 | Journal article
DOI: 10.1002/pbc.23402
PMID: 22162424
Source: Self-asserted source
Johannes Wolff

Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database.

Journal of neuro-oncology
2011-10-01 | Journal article
DOI: 10.1007/s11060-011-0718-y
PMID: 21964697
Source: Self-asserted source
Johannes Wolff

Advanced atypical teratoid/rhabdoid tumor (ATRT) treated with intensive multimodal approach shows continued response to sarcoma type salvage therapy.

Pediatric blood & cancer
2011-09-15 | Journal article
DOI: 10.1002/pbc.23322
PMID: 21922648
Source: Self-asserted source
Johannes Wolff

Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience.

Journal of neuro-oncology
2011-08-20 | Journal article
DOI: 10.1007/s11060-011-0677-3
PMID: 21858608
PMC: PMC3990187
Source: Self-asserted source
Johannes Wolff

Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center.

Anticancer research
2011-06-01 | Journal article
PMID: 21737651
Source: Self-asserted source
Johannes Wolff

Thalamic high-grade gliomas in children: a distinct clinical subset?

Neuro-oncology
2011-06-01 | Journal article
DOI: 10.1093/neuonc/nor045
PMID: 21636712
PMC: PMC3107103
Source: Self-asserted source
Johannes Wolff

Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapies.

Statistics in medicine
2011-05-17 | Journal article
DOI: 10.1002/sim.4249
PMID: 21590700
PMC: PMC3115413
Source: Self-asserted source
Johannes Wolff

Pediatric neuro-oncology in small centers--quality control of network support: the HIT-GBM experience.

Anticancer research
2011-02-01 | Journal article
PMID: 21378352
Source: Self-asserted source
Johannes Wolff

Canine astrocytic tumors: a comparative review.

Veterinary pathology
2010-11-08 | Journal article
DOI: 10.1177/0300985810389543
PMID: 21059873
Source: Self-asserted source
Johannes Wolff

Which therapy works better in choroid plexus carcinomas?

Journal of neuro-oncology
2010-10-26 | Journal article
DOI: 10.1007/s11060-010-0372-9
PMID: 20976614
Source: Self-asserted source
Johannes Wolff

Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.

European journal of cancer (Oxford, England : 1990)
2010-10-01 | Journal article
DOI: 10.1016/j.ejca.2010.05.010
PMID: 20886683
PMC: PMC3025305
Source: Self-asserted source
Johannes Wolff

Measuring performance status in pediatric patients with brain tumors--experience of the HIT-GBM-C protocol.

Pediatric blood & cancer
2010-09-01 | Journal article
DOI: 10.1002/pbc.22566
PMID: 20658624
Source: Self-asserted source
Johannes Wolff

High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study.

Journal of neuro-oncology
2010-08-08 | Journal article
DOI: 10.1007/s11060-010-0334-2
PMID: 20694800
Source: Self-asserted source
Johannes Wolff

Sorafenib plus valproic acid for infant spinal glioblastoma.

Journal of pediatric hematology/oncology
2010-08-01 | Journal article
DOI: 10.1097/mph.0b013e3181d74702
PMID: 20463608
Source: Self-asserted source
Johannes Wolff

Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.

BMC cancer
2010-06-02 | Journal article
DOI: 10.1186/1471-2407-10-252
PMID: 20525214
PMC: PMC2891637
Source: Self-asserted source
Johannes Wolff
Items per page:
Page 1 of 3

Peer review (1 review for 1 publication/grant)

Review activity for Journal of neuro-oncology. (1)
How many people are using ORCID?